Last update 05 Nov 2024
Luliconazole
Last update 05 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Luconac Solution, Luliconazole (JAN/USAN/INN), Lulifin + [12] |
Target |
Mechanism fungal CYP51A1 inhibitors(Fungal CYP51A1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (11 Apr 2005), |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC14H9Cl2N3S2 |
InChIKeyYTAOBBFIOAEMLL-REQDGWNSSA-N |
CAS Registry187164-19-8 |
Related
15
Clinical Trials associated with LuliconazoleEfficacy Evaluation of Loaded Nanostructured Lipid Carriers (NLC) with Luliconazole in Treatment-Resistant Dermatophytosis
A Comparative study to evaluate the efficacy and safety of topical Luliconazole versus topical Ciclopirox olamine among patients with Tinea corporis/cruris - NIL
A randomized study to evaluate and compare the efficacy of emollient versus topical luliconazole in the maintenance of remission of recurrent dermatophytosis after adequate systemic treatment.
100 Clinical Results associated with Luliconazole
Login to view more data
100 Translational Medicine associated with Luliconazole
Login to view more data
100 Patents (Medical) associated with Luliconazole
Login to view more data
199
Literatures (Medical) associated with Luliconazole01 Nov 2024Current drug research reviews
Assessing the Efficacy of Berberine Hydrochloride-loaded Transethosomal
Gel System in Treating Dermatophytosis Caused by Trichophyton rubrum
in ex-vivo, in-vitro and in-vivo Models
Article
Author: Mishra, Koushlesh Kumar ; Tiwari, Abhishek ; Singh, Sunil ; Kaur, Chanchal Deep ; Sharma, Ajay ; Tiwari, Varsha
Background::
Dermatophytosis is the most common dermatological disorder worldwide.
Many drugs are available in the market for the treatment of dermatophytosis, but they have
had limited success due to the stratum corneum barrier, antifungal resistance, drug permeation,
drug retention in skin layers, etc. Thus, there is a constant need for new topical compounds that
are effective against dermatophytosis. Berberine-hydrochloride is an attractive candidate to become
an antifungal drug, and by using nanotechnology, it achieves deeper penetration in skin layers
with enhanced permeability through the stratum corneum.
Methods::
In this study, we developed an oleic acid-containing berberine-hydrochloride-loaded
transethosomal gel for effective treatment of dermatophytosis by Trichophyton rubrum. Berberine-
hydrochloride-loaded transethosomal gels were fabricated using the hot homogenization
method, followed by the incorporation of transethosomes into the gel-based system using carbopol
934. Transethosomal gel was characterized by physicochemical properties, in vitro drug release,
ex-vivo permeation studies, CLSM visualization, antifungal activity, histopathological evaluation,
and dermatokinetic study.
Results::
Berberine-hydrochloride-loaded transethosomes seemed to be spherical and found in a
range between 200-300 nm. Berberine-hydrochloride-loaded transethosomal gel formulation also
exhibited controlled ex-vivo permeation of berberine-hydrochloride over 24 hr through excised rat
skin, and CLSM confirmed deeper penetration into skin layers. The in vivo study revealed that
transethosomal gel had a healing effect on the skin of Wistar rats infected with Trichophyton
rubrum and was better than luliconazole cream. The histopathological evaluation confirmed its
safety, and the dermatokinetic study showed transethosomal gel superiority over marketed cream.
Conclusion::
Therefore, the incorporation of berberine hydrochloride-loaded transethosomal
nanosystems into the gel has the potential to enhance antifungal activity and permeation through
transdermal drug delivery.
01 Sep 2024Naunyn-Schmiedeberg's archives of pharmacology
Polymeric micelle gel with luliconazole: in vivo efficacy against cutaneous candidiasis in Wistar rats
Article
Author: Narang, Raj Kumar ; Singh, Gurmeet
The objective of this research was focused on the design and development of luliconazole-loaded polymeric micelle hydrogel (LUL-PM-CHG) using quality by design (QbD) principle to improve the penetration and retention of LUL in the skin. The optimization of the formulation involved the utilization of a Box-Behnken design with three factors and three levels. The impact of specific formulation variables, namely the ratio of poloxamer P123 and F127, sonication time, and the quantity of drug, was investigated in terms of particle size, micellar incorporation efficiency, and polydispersity index. The LUL-loaded P123/F127 mixed micelles involved the thin film hydration method for thin preparation. The characteristics of optimized formulation include a particle size of 226 ± 8.52 nm, a polydispersity index (PDI) of 0.153 ± 0.002, a zeta potential (ZP) of 30.15 ± 2.32 mV, and a micellar incorporation efficiency (MIE) of 88.38 ± 3.84%. In vitro release studies indicated a sustained release of LUL-PM-CHG for a duration of up to 8 h. The MIC, GI50, and GI90 of different formulations on Candida albicans were determined using both the microtiter broth dilution method and the plate method and showed that LUL-PM-CHG exhibited the highest antifungal activity compared to the other formulations, with MIC values of 3.25 ± 0.19 ng/mL, GI50 values of 37.11 ± 2.89, and GI90 values of 94.98 ± 3.41 The study also measured the % of inhibition activity and the generation of intracellular reactive oxygen species (ROS) using flow cytometry. LUL-PM-CHG showed the highest percentage of inhibition (75.5%) and ROS production (MFI-140951), indicating its enhanced activity compared to LUL-CHG and LUL. Fungal infection was induced in Wistar rats using immunosuppressant's treatment followed by exposure to C. albicans. Finally, in vivo fungal scaling and histopathological studies indicated a reduction in fungal infection in Wistar rat skin after treatment. The obtained results suggested that LUL-PM can serve as a promising formulation to enhance luliconazole antifungal activity and increase patient compliance.
01 Sep 2024JOURNAL DE MYCOLOGIE MEDICALE
Asymptomatic colonization of stray dogs and domestic cats with Trichophyton mentagrophytes II in Northern Iran
Article
Author: Seyedmousavi, Seyedmojtaba ; Nasrollahi Omran, Ayatollah ; Hedayati, Mohammad Taghi ; Haghani, Iman ; Oladzad, Vahid ; Nabili, Mojtaba ; Guillot, Jacques
BACKGROUND:
Despite changes in the epidemiology of dermatophyte infections, the incidence of fungal infections associated with Trichophyton species still remains high among dogs and cats. The objective of the present study was to isolate and characterize dermatophytes from dogs and cats in Iran.
METHOD:
From December 2022 to May 2023, skin and hair samples were collected from symptomatic and asymptomatic cats and dogs in Mazandaran, a northern province of Iran. The samples were then inoculated into Mycosel™ Agar. Dermatophyte isolates were identified by sequencing the internal transcribed spacer region. Antifungal susceptibility tests were conducted using the Clinical and Laboratory Standards Institute (CLSI-M38-A3).
RESULT:
Of the 250 samples collected (from 200 dogs and 50 cats), 20 (from 19 dogs and one cat) (8.0 %) were positive for dermatophyte growth. Based on sequence and phylogenetic analysis, all isolates belonged to T. mentagrophytes II*. Of these positive samples, 14 (70.0 %), 3 (15.0 %), 2 (10.0 %), and 1 (2.0 %) were isolated from asymptomatic stray dogs, symptomatic stray dogs, symptomatic domestic dogs, and symptomatic cats, respectively. Luliconazole and terbinafine displayed potent activity against all T. mentagrophytes isolates, with Minimum inhibitory concentration (MIC) values of 0.016 µg/ml. Miconazole and griseofulvin demonstrated higher MIC (1 and 8 µg/ml).
CONCLUSION:
The present study indicated that T. mentagrophytes II* asymptomatic carriage is frequent in stray dogs in Iran. The potential risk to public health needs to be evaluated However, T. mentagrophytes genotype VIII, considered as an endemic and emerging human pathogenic clone in several countries, was not detected during the present survey.
1
News (Medical) associated with Luliconazole10 Sep 2015
First in Class
100 Deals associated with Luliconazole
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01980 | Luliconazole |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Tinea Manus | US | 20 Feb 2018 | |
| Onychomycosis | JP | 22 Jan 2016 | |
| Candidiasis, Cutaneous | CN | 27 Jun 2012 | |
| Mycoses | KR | 01 Feb 2010 | |
| Tinea corporis | JP | 31 Jul 2005 | |
| tinea cruris | JP | 31 Jul 2005 | |
| Tinea Pedis | JP | 31 Jul 2005 | |
| Candidiasis | JP | 11 Apr 2005 | |
| Tinea | JP | 11 Apr 2005 | |
| Tinea Versicolor | JP | 11 Apr 2005 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Candidiasis, Chronic Mucocutaneous | Discovery | US | 11 Jan 2011 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 4 | 75 | (Luliconazole Cream 1%) | jjdzyiweid(atkkbxyuut) = ouodhbhsny breohtldyl (xupblidwxq, sqtokgsemw - gskdqaujxc) View more | - | 27 Nov 2019 | ||
Vehicle Cream (Vehicle Cream) | jjdzyiweid(atkkbxyuut) = ztqxtnlycz breohtldyl (xupblidwxq, zrfucaddgm - sodpnyqybv) View more | ||||||
Phase 4 | 30 | (Tinea Pedis) | pwzcrgoxvl(dfsjibwlok) = mjykxexqnu vymcfgjrpd (ifioibekla, joannapyka - qmcrdulfpd) View more | - | 27 Nov 2019 | ||
(Tinea Cruris) | bgwiwjsknd(zgnzvklcqf) = nnrhsevbxy twfgcrayab (mqkhhyxsaw, custamscvi - rfgbjtuvno) View more | ||||||
Phase 4 | 20 | vjmruygcny(qpswncknrw) = chmhjkmqsm uhxjsmmgaq (ukfzdkrauq, ankpvzjjwc - kydavwcmav) View more | - | 27 Nov 2019 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free